ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, ANI Pharmaceuticals, Inc. keeps $9 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 6
in 57 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals, Inc. develops and markets specialty and generic medicines and manufactures a broad range of dose forms, from injectables and softgel capsules to oral solid doses, semi-solids, liquids, topicals, controlled substances, and potent products. Listed on NASDAQ as ANIP, the company operates in pharmaceuticals and generated $883.4 million of revenue in FY2025.
Today's Snapshot
ANIP is trading slightly lower at 70.47, while its sector was weaker. So far today, ANIP is within 0.7% of its 52-week low of 69.96. ANI Pharmaceuticals highlighted faster growth in rare-disease drugs at a Wells Fargo investor conference.
Trading Volume
Below 10d avg (310.6K)
110.7K
vs S&P 500 Today
Moderate Outperformance
+0.28%
Updated: September 10, 2026 at 19:22 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$71.95 - $80.63Sell
- RSI (14)34.91Neutral
- Stochastic %K (14, 3, 3)5.11Buy
- MACD Level (12, 26)-2.04Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.